Joseph Harry Antin MD

Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

44 Binney St# Dana-FarBoston, MA 02115
Phone+1 617-632-3667
Fax+1 617-632-5175

Dr. Antin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Antin's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1981 - 1983
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Weill Cornell MedicineClass of 1978

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1986 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017

Clinical Trials

Blood and Marrow Transplant Clinical Research Network
COMPLETED
NA
Phase I Study of Sequential Cord Blood Transplants
COMPLETED
PHASE1
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Venetoclax-augmented RIC allogeneic HCT with PTCy-based GVHD prophylaxis and venetoclax/azacitidine maintenance for poor risk MDS and AML.
H Moses Murdock, Kyle Hebert, Mahasweta Gooptu, Roman Shapiro, Gregory Abel
Transplantation and Cellular Therapy. 2026-08-19
Pound wise, penny foolish: improving value in SCD care.
Amar H Kelkar, Joseph H Antin
Blood. 2026-08-13
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
Corey Cutler, Haesook T Kim, Hassan El Banna, Elizabeth Halloran, Emily Matozel
Journal of Clinical Oncology. 2026-06-01

Journal Articles

Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Pr...
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025
Dana-Farber Researchers to Showcase Pivotal Transplant and Cellular Therapy Findings at 2025 Tandem MeetingsFebruary 12th, 2025
ASBMT NewsOctober 13th, 2018

Grant Support

BMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumDANA-FARBER CANCER INST2001–2031
A Randomized Trial Of Tac/Mtx/Bortezomib VS Tac/Mtxplacebo In Allogeneic HSCTNational Heart, Lung, And Blood Institute2011
Novel Approaches To Graft-Versus-Host Disease PreventionNational Cancer Institute2009–2011
Mechanisms Of GVHDNational Cancer Institute2009–2011
Administrative CoreNational Cancer Institute2009–2011